HCQ/ CQ failure; AZ/ Catalent’s deal; Sinovac’s CoronaVac and Lilly’s Olumiant trial results
Jun 16, 2020
The US FDA nullified the Emergency Use Authorization (EUA) granted to chloroquine phosphate and hydroxychloroquine sulfate to treat COVID-19. The regulatory authority had g...
Read More
In the race to fight SARS-CoV-2: Merck, ISB; ViiV; Genalyte gears up
Apr 28, 2020
Merck has collaborated with the Seattle-based Institute for Systems Biology (ISB) to further study novel coronavirus SARS-CoV-2. The primary goal of the collaboration will ...
Read More
GBT, Syros; Takeda, Cevance collaborates; IND application to ZN-c3
Dec 19, 2019
Global Therapeutics and Syros Pharmaceuticals have teamed up to move forward to discover, develop and market novel Sickle cell disease and beta-thalassemia therapies. ...
Read More
Omega’s sixth funding round; Correvio’s drug failure; and BIMA acquisition
Dec 12, 2019
A leading global international investment firm, Omega Funds has announced the closure of its sixth fundraising USD 438 Million. More than decade old Life Sciences-based inv...
Read More
Acquisition of ArQule; Synthorx; and Zentalis nabs a raise
Dec 10, 2019
Merck is set to complete the already planned purchase of the ArQule for USD 2.7 Billion. Under the terms of the agreement, Merck will pay USD 20 for each share in cash for ...
Read More
Cumberland’s methotrexate product gets approval in the US; Baker Brothers purchases stake in Kodiak’s KSI-301; Sanofi offloads Seprafilm unit to Baxter
Dec 3, 2019
Cumberland Pharmaceuticals has recently received approval from the US FDA for its RediTrex injection for the treatment of rheumatoid arthritis. Cumberland pharmaceuticals p...
Read More
Toujeo to treat Type 1 Diabetes; TauRx for Alzheimer’s patients
Nov 28, 2019
Sanofi’s Toujeo has received FDA recommendation for its expanded use in Type 1 Diabetes. Toujeo is an insulin glargine injection to control the highs and lows of blood su...
Read More
Novartis buys Medicines Co. for USD 9.7 Billion
Nov 26, 2019
Novartis plans to buy The Medicines Company for USD 9.7 Billion to gain access to a heart drug inclisiran, almost ready to get into the market. Under the terms of the deal,...
Read More
GHO to advance healthcare in Europe; Truvian nets USD 27.1 Mn; Lilly plans its diabetes portfolio expansion
Nov 21, 2019
Global Healthcare Opportunities (GHO) Capital, a London-based healthcare investment firm, has recently netted USD 1.1 Billion to advance European healthcare. The company pl...
Read More
Nordisk ties up with Dicerna; Pfizer’s drug gets FDA nod
Nov 19, 2019
Novo Nordisk has announced to enter into a collaboration with Dicerna’s RNAi platform to focus on metabolic and liver-related diseases. The companies will be focusing to ...
Read More
AbbVie Sells bonds to Fund Allergan takeover
Nov 14, 2019
AbbVie has traded off its bonds worth USD 30 Billion to finance the purchase of the Allergan. AbbVie this year in June has agreed to buy Allergan for USD 63 Billion,...
Read More
FDA declines the approval of Lipocine’s testosterone drug; Novartis Sandoz to buy Aspen Pharmacare Japanese Unit
Nov 12, 2019
The US FDA for the third time has refused to give approval to Lipocine’s oral testosterone drug, Tlando. The drug is an oral testosterone replacement therapy in clinical ...
Read More
AZ sells EU rights for Schizophrenia to Cheplapharm; Astellas, Pandion unite to extract the potential of immunomodulation; Pear therapeutics on a journey to develop digital GI treatments with Ironwood
Oct 31, 2019
AstraZeneca has announced the licensing-out of two of its drugs Seroquel and Seroquel XR in Europe and Russia to Cheplapharm Arzneimittel GmbH. According to the deal signed...
Read More
FDA approval to AZ’s Farxiga for heart failure; GSK divests two travel vaccines to Bavarian Nordic; New breakthrough therapy for Cystic Fibrosis
Oct 22, 2019
The US FDA today has given its nod to Trikafta (elexacaftor/ivacaftor/tezacaftor) of Vertex Pharmaceuticals, the first of its kind triple combination therapy for the patien...
Read More
ImaginAb joins hands with AstraZeneca, Pfizer, Takeda
Oct 15, 2019
ImaginAb has collaborated with AstraZeneca, Pfizer and Takeda to develop technology to facilitate tumour imaging and monitoring inside the cells. ImaginAb is an emerging im...
Read More
